Perkins Capital Management Inc. lowered its holdings in IRIDEX Co. (NASDAQ:IRIX) by 39.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 53,250 shares of the medical equipment provider’s stock after selling 35,350 shares during the quarter. Perkins Capital Management Inc. owned about 0.46% of IRIDEX worth $406,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in IRIX. Neuberger Berman Group LLC purchased a new position in IRIDEX during the 3rd quarter worth approximately $141,000. Lyon Street Capital LLC grew its stake in IRIDEX by 4.5% during the 3rd quarter. Lyon Street Capital LLC now owns 442,647 shares of the medical equipment provider’s stock worth $4,148,000 after buying an additional 19,059 shares during the last quarter. Osborne Partners Capital Management LLC purchased a new position in IRIDEX during the 3rd quarter worth approximately $673,000. Ingalls & Snyder LLC purchased a new position in IRIDEX during the 3rd quarter worth approximately $234,000. Finally, Susquehanna International Group LLP purchased a new position in IRIDEX during the 2nd quarter worth approximately $196,000. Institutional investors and hedge funds own 49.07% of the company’s stock.
In related news, CEO William M. Moore acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was bought at an average cost of $7.84 per share, with a total value of $39,200.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 5.01% of the stock is currently owned by company insiders.
IRIDEX Co. (NASDAQ:IRIX) traded up $0.19 during trading hours on Friday, reaching $7.23. The company had a trading volume of 22,729 shares, compared to its average volume of 20,094. The stock has a market cap of $83.72, a P/E ratio of -4.23 and a beta of 1.19. IRIDEX Co. has a 12-month low of $6.67 and a 12-month high of $16.37.
A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded IRIDEX from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Roth Capital restated a “buy” rating and set a $13.00 price target on shares of IRIDEX in a research note on Friday, November 3rd.
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.